Hopefully, inhibition of δ-secretase will simultaneously block APP and Tau proteolytic cleavage, mitigate Abeta and Tau pathology and decrease neurodegeneration, alleviating the cognitive deficits in AD patients. Here, APP is linked to Alzheimer disease.